Giovanni D’Arena, Rosaria De Filippi, Antonio Pinto
Abstract
The humanized anti-CD52 monoclonal antibody alemtuzumab is currently employed for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) [1],[2]. Despite a single description of a case of aut...
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The humanized anti-CD52 monoclonal antibody alemtuzumab is currently employed for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) [1],[2]. Despite a single description of a case of aut...
Key concepts: Alemtuzumab, CD52, Chronic lymphocytic leukemia, Autoimmune hemolytic anemia, Medicine, Monoclonal antibody, CD20, Monoclonal